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Aims Cardiac amyloidosis remains a great challenge for the cardiologist. One of the three main aetiological forms,
transthyretin-related hereditary amyloidosis (ATTRm), can present with several phenotypes, depending mainly on
the specific mutation. We aimed to characterize the phenotype of patients with ATTRm due to Ile68Leu mutation,
comparing them to patients with wild-type transthyretin amyloidosis (ATTRwt).
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Methods
and results
Data of 67 Ile68Leu ATTRm patients from two Italian referral centres (Bologna and Florence) were retrospectively analysed
and compared to those of 82 ATTRwt patients. Fifty-five unaffected mutation carriers were also analysed. Cumulative
disease onset was 50% at age 71. A total of 56/67 (84%) patients had a predominantly cardiac phenotype at presentation
with concentric increase in left ventricular wall thickness [median 17 mm], and normal or near normal left ventricular
ejection fraction (79% of patients). Low QRS voltages were present only in 29% of patients but voltage/mass ratio was
low (0.5). Carpal tunnel syndrome was noted in 43%. The overall phenotypic profile was similar to ATTRwt but Ile68Leu
ATTRm patients typically presented younger (median 71 vs. 78 years) and were more likely to have (mild) symptomatic
neurological involvement (19% vs. 2%). Male prevalence was 44% in unaffected mutation carriers and 78% in affected patients.
Age-adjusted survival was comparable between groups.
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Conclusions Ile68Leu ATTRm is a cause of familial amyloidotic cardiomyopathy endemic in central-northern Italy and presents as
hypertrophic/restrictive cardiomyopathy quite similar to ATTRwt. Male preponderance is present in affected patients
but not in unaffected mutation carriers. Age-adjusted survival is similar to ATTRwt.
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Introduction
Hereditary transthyretin (TTR) amyloidosis (ATTRm) is an auto-
somal dominant disorder caused by the extracellular deposition
of amyloid fibrils derived from TTR, a transport protein mainly
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synthesized by the liver.1,2 ATTRm is characterized by a high geno-
typic heterogeneity, with over 120 amyloidogenic point mutations
described to date.3 The clinical spectrum can vary widely from
an exclusively neurological to a predominantly cardiac phenotype.4
Only a small number of TTR variants are associated with a mainly
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cardiac involvement [also known as familial amyloidotic cardiomy-
opathy (FAC)] and have been identified in well-defined popula-
tions, such as Val122Ile in USA patients of African descent,5–7
Leu111Met in Danish kindred8 and Thr60Ala in north-western
Ireland.9 Non-mutant protein (i.e. wild-type TTR) can also cause
amyloidotic cardiomyopathy (ATTRwt) and is frequently associated
with carpal tunnel syndrome (CTS)10 with very little or no neu-
ropathy.
We previously reported that >15% of Italian ATTRm patients
referred to specialized Amyloidosis Centres have a late-onset
cardiac phenotype, which is almost indistinguishable from ATTRwt,
and that a single TTR variant (Ile68Leu) accounts for many of these
cases.11 In the present study, we carry out the first comprehensive
description of the clinical profile and outcome of patients affected
by Ile68Leu ATTRm and compare them to a cohort of patients
diagnosed as ATTRwt who presented over the same period and in
the same geographic areas.
Methods
Clinical setting and study population
Data regarding patients with Ile68Leu ATTRm and ATTRwt evaluated
in two Italian referral Centres (Bologna and Florence) between January
1993 and December 2017 were extracted from dedicated prospective
local databases that include baseline and follow-up data. The main clini-
cal/instrumental variables at presentation—including diagnostic route,
symptoms at disease onset, previous (mis)diagnoses, main labora-
tory tests, cardiac and neurological assessments, electrocardiographic
and echocardiographic details—were analysed. Follow-up data were
obtained from the last visit or by telephone interview in those without
any contact in the last 6months. The study was approved by the local
ethics committee.
We also compared data from our study population with published
data on patients with Val122Ile ATTRm from the THAOS registry.12
Definitions and classifications
A diagnosis of TTR-related amyloidotic cardiomyopathy (AC) was
made when diastolic interventricular septum thickness was >12mm
on echocardiography in the absence of other causes of ventricular
hypertrophy and in association with at least one of the following:
(i) evidence of TTR deposits by immunohistochemistry in a tissue
biopsy; (ii) non-invasive documentation of intense cardiac uptake
(visual score 2 or 3) on bone-tracer scintigraphy (99mTc-DPD or
99mTc-HMDP) with exclusion of monoclonal gammopathy on serum
and urine samples.
The phenotype at presentation was defined as: (i) ‘predominantly
cardiac’, based on echocardiographic evidence of AC with no signs
or symptoms of neurological involvement (erectile dysfunction in men
aged >50 and CTS were not considered signs of neurological involve-
ment per se as they are not infrequent in the general population); (ii)
‘predominantly neurological’, if neurological involvement was detected
clinically in absence of signs of cardiac amyloidosis; and (iii) ‘mixed’
(cardiac/neurologic) for all other cases.
Neurological symptoms were staged according Coutinho et al.13: 0,
no symptoms; 1, unimpaired ambulation, mostly mild sensory, motor,
and autonomic neuropathy in the lower limbs; 2, assistance with ambu-
lation required; mostly moderate impairment progression to lower ..
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.. limbs, upper limbs, and trunk; 3, wheelchair-bound or bedridden;
severe sensory, motor, and autonomic involvement of all limbs. Auto-
nomic involvement was defined by presence of orthostatic hypotension
(decline >20mmHg in systolic blood pressure, or>10mmHg in dias-
tolic blood pressure upon standing), urinary incontinence or gastroin-
testinal symptoms (diarrhoea, constipation, fecal incontinence). CTS
history was considered positive in the presence of typical symptoms or
of previous surgery for median nerve decompression. ‘Vitreal involve-
ment’ refers to visual impairment leading to ophthalmologic detection
of vitreous opacities.
Electrocardiogram
Standard definitions were used for the interpretation of 12-lead elec-
trocardiograms (ECGs). LowQRS voltages were defined as QRS ampli-
tude ≤0.5mV in all limb leads, or≤1mV amplitude in all precordial
leads.14 The voltage/mass ratio was defined as total QRS score divided
by left ventricular mass measured on echocardiogram indexed to body
surface area. QT prolongation was defined as QTc ≥450ms in males
and≥ 470ms in females.
Echocardiography
Echocardiographic images were obtained from the standard parasternal
long-axis, parasternal short-axis, apical and subcostal views. Chamber
and left ventricular ejection fraction (LVEF) quantification was per-
formed according to the recommendations of the American Society
of Echocardiography.15 Left ventricular mass, diameters and wall thick-
ness were evaluated by M-mode. Patterns of hypertrophy were defined
as previously described.16 A restrictive filling pattern was defined as
E wave deceleration time<150ms and E/A ratio> 2.5 on transmitral
pulsed Doppler. Myocardial contraction fraction was calculated accord-
ing to the formula described by Maurer and colleagues.17
Genotyping
Transthyretin gene analysis was carried out in all patients. Genomic
DNA was isolated from whole peripheral blood by standard tech-
niques. Exons 2, 3 and 4 of the TTR gene (accession number M11844)
were amplified by polymerase chain reaction (Takara ExTaq poly-
merase) using primers previously described.18 Amplified DNA frag-
ments were directly sequenced using ABI Prism 3130 automated
sequence.
Statistical analysis
Continuous variables are expressed as median and interquartile range
(IQR) and categorical variables as number of patients and frequen-
cies/percentage. The clinical and instrumental differences between the
subtypes of cardiac amyloidosis were analysed using the Wilcoxon
rank-sum test for continuous variables and 𝜒2 test for categorical
variables. Bonferroni correction for multiple comparisons was applied
to control the family-wise error rate. Kaplan–Meier curves were
reported to graphically analyse overall survival; the log-rank test was
used to compare freedom from overall death between subgroups.
Clinical, laboratory, electrocardiographic and echocardiographic vari-
ables were evaluated with a Cox regression model to identify inde-
pendent predictors of survival in Ile68Leu patients. Non-correlated
variables with P-values ≤0.2 at univariate analysis were considered in
the multivariate analysis. Model building followed a backward-stepwise
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Table 1 Baseline characteristics of the study population
Ile68Leu (n= 67) ATTRwt (n= 82) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Families, n 63 –
Males, n (%) 52 (78) 73 (89) 0.059
Age at diagnosis, years, median (IQR) 71 (65–78) 78 (72–81) <0.001*
Disease duration, months, median (IQR) 10 (3–24) 10 (3–21) 0.872
BMI, kg/m2, median (IQR) 25 (23–27) 25 (23–28) 0.905
Heart rate, b.p.m., median (IQR) 75 (65–80) 75 (67–83) 0.833
SBP, mmHg, median (IQR) 120 (110–132) 120 (110–130) 0.368
DBP, mmHg, median (IQR) 80 (70–80) 70 (60–80) 0.007
eGFR, mL/min, median (IQR) 54 (45–74) 52 (43–65) 0.276
Diagnostic route, n (%) 0.093
Incidental 4 (6) 10 (12)
Neurological 1 (1) 0 (0)
Cardiac 59 (88) 72 (88)
Family screening 3 (5) 0 (0)
Neurological symptoms according to
Coutinho classification, n (%)
0.001*
0 54 (81) 80 (98)
1 13 (19) 2 (2)
2 0 (0) 0 (0)
3 0 (0) 0 (0)
Autonomic involvement, n (%) N/A
Orthostatic hypotension 3 (4) 0 (0)
Urinary incontinence 1 (1) 0 (0)
Gastrointestinal symptoms 1 (1) 0 (0)
Carpal tunnel syndrome, n (%) 29 (43) 30 (37) 0.406
Vitreal involvement, n (%) 0 (0) 0 (0) N/A
Amyloidotic cardiomyopathy, n (%) 64 (96) 82 (100) 0.089
NYHA class III/IV, n (%) 18 (27) 27 (33) 0.423
NT-proBNP, pg/mL, median (IQR)† 3287 (1745–5658) 4800 (1706–12376) 0.229
Phenotype, n (%) 0.062
Predominantly cardiac 56 (84) 77 (94)
Predominantly neurological 3 (4) 0 (0)
Mixed 8 (12) 5 (6)
ATTRwt, wild-type transthyretin amyloidosis; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; N/A,
not applicable; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
*P-values with statistical significance persisting after Bonferroni correction.
†Data available in 34 Ile68Leu and in 61 ATTRwt patients.
approach, term of significance was tested with the Wald 𝜒2 test with
cut-off P-value of 0.1 for removal and 0.05 for addition. Harrell’s
C-statistic was used to assess the goodness of fit of Cox regression
models. A P-value <0.05 (2-sided) was considered significant. All anal-
yses were carried out with Stata/SE 14.2 forWindows (StataCorp LLC,
College Station, TX, USA).
Results
Clinical profile
The study cohort consisted of 67 subjects with heterozygous
Ile68Leu ATTRm from 63 unrelated families (Table 1), mainly
from Emilia-Romagna and Tuscany regions (94%), with the excep-
tion of two patients from Lombardy and two from Marche.
Sixty-four patients were probands and three were diagnosed by ..
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. family screening. Family screening, which included genetic testing,
clinical evaluation, ECG and echocardiography, also identified 55
unaffected mutation carriers with no signs of amyloidosis, includ-
ing a 48-year-old homozygous man. In detail, 24/55 (44%) of the
unaffected carriers were males, with a median age of 49 (43–56),
and a mean age of 51±11 years. Echocardiogram showed normal
wall thickness in all cases with the exception of a single patient
with hypertension and obesity in whom diastolic interventricular
septum thickness was 12mm. ECG was within normal limits in
52/55 cases with non-specific repolarization abnormalities in two
patients and left anterior hemiblock in a single case. The compara-
tor group consisted of 82 ATTRwt patients. In 4 Ile68Leu ATTRm
and in 10 ATTRwt patients the diagnosis of AC was incidental
following bone-tracer scintigraphy performed for oncological or
rheumatological reasons. In all but one of the remaining probands
the diagnostic workup was initiated by cardiac symptoms.
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Table 2 Electrocardiographic findings
Ile68Leu (n= 67) ATTRwt (n= 82) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Atrial fibrillation, n (%) 20 (30) 37 (45) 0.056
Permanent pacemaker, n (%) 6 (9) 12 (15) 0.324
First degree AV block*, n (%) 13 (21) 15 (21) 0.844
Total QRS score, mV, median (IQR) 114 (98–135) 118 (101–141) 0.548
Low QRS voltages, n (%) 18 (29) 19 (25) 0.603
Voltage/mass, mV/g/m2 BSA, median (IQR) 0.5 (0.4–0.7) 0.5 (0.5–0.7) 0.823
Right bundle branch block*, n (%) 12 (20)† 14 (20)‡ 0.963
Left bundle branch block*, n (%) 8 (13) 8 (11) 0.742
Left anterior hemiblock*, n (%) 27 (44)† 29 (41)‡ 0.744
Any infarct pattern*, n (%) 38 (63) 44 (63) 0.955
Ischaemic pattern* (negative T waves), n (%) 28 (47) 32 (46) 0.914
QTc interval*, ms, median (IQR) 474 (447–495) 454 (433–495) 0.010
Prolonged QTc interval*, n (%) 41 (67) 32 (46) 0.013
Normal ECG, n (%) 5 (8) 3 (4) 0.295
ATTRwt, wild-type transthyretin amyloidosis; AV, atrioventricular; BSA, body surface area; ECG, electrocardiogram; IQR, interquartile range.
*Referred to patients without pacemaker.
†Including 5 patients with left anterior hemiblock + right bundle branch block.
‡Including 6 cases with left anterior hemiblock + right bundle branch block.
No comparison is associated with statistical significance after Bonferroni correction.
In the Ile68Leu group, the diagnosis of AC was reached inva-
sively by endomyocardial biopsy in 25/67 patients (37%) and
non-invasively in 42 (63%). In the ATTRwt group, the diagnosis
was reached invasively by endomyocardial biopsy in 59/84 patients
(70%) and non-invasively in the other 25 (30%).
The main clinical findings are reported in Table 1. Median
age at diagnosis was 7 years younger in Ile68Leu patients [71
(65–78) vs. 78 (72–81); P< 0.001]. At baseline evaluation, 84% of
Ile68Leu patients showed a predominantly cardiac phenotype, 12%
had a mixed phenotype with a predominant cardiac involvement
and 4% had a predominantly neurologic phenotype. On specific
questioning, 13 Ile68Leu patients (19%) reported mild neurological
motor symptoms on walking (vs. 2 patients, 2% of ATTRwt;
P= 0.001). A history of CTS was reported by 43% of Ile68Leu
ATTRm patients and by 37% of ATTRwt (P= 0.406). Ninety-six
percent of Ile68Leu ATTRm group and 100% of ATTRwt had a
cardiomyopathy diagnosed on echocardiography. Heart failure was
the reason that most frequently brought Ile68Leu ATTRm patients
to medical attention (53/67 patients, 79%). At presentation, the
same number of patients had signs or symptoms of heart failure
and 18/67 of these (27%) were in New York Heart Association
(NYHA) class III/IV. Sixteen/67 patients (24%) reported a reduced
exercise tolerance, while in 37/67 patients (55%) dyspnoea was
associated with right heart failure. All patients with heart failure
were treated with variable doses of diuretics.
Nine Ile68Leu ATTRm patients with no neurological symptoms
underwent a thorough neurological examination, with detection
of a mild lower limb sensory impairment in five patients and mild
mixed lower limbs sensory-motor impairment in two. Of the 18
unaffected mutation carriers examined by the neurologists, two
were found to have mild lower limb sensory impairment and three
had possible initial manifestations of CTS. .
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.. Of the three Ile68Leu ATTRm patients diagnosed by family
screening, one (an 80-year-old male) had signs of cardiac involve-
ment with previous heart failure hospitalization, the second was
a 63-year-old female with mild symptomatic peripheral neuropa-
thy, and the third was a 58-year-old male with mild symptomatic
peripheral neuropathy, borderline echocardiographic findings and
mild cardiac uptake (visual score= 1) on 99mTc-DPD scintigraphy.
Electrocardiographic findings are reported in Table 2. Twelve-
lead ECG was normal in only 8% of Ile68Leu ATTRm patients.
The ECG profile of ATTRwt patients was similar with the only
exception of a slightly higher prevalence of atrial fibrillation (45%
vs. 30%, P= 0.056). In both groups, prevalence of low QRS voltages
was observed in less than 30% of patients.
The main echocardiographic findings are reported in Table 3. No
significant differences were present between Ile68Leu ATTRm and
ATTRwt patients. Specifically, the mean value of left ventricular wall
thickness ranged 15–19mm (median 17mm) and LVEF was ≥40%
in 79% of Ile68Leu ATTRm patients.
Male and female Ile68Leu patients had a similar profile (online
supplementary Tables S1–S3) with the only exception of a higher
prevalence of CTS in males (50% vs. 20%, P= 0.039) and a mildly
older age at diagnosis in females (median 75 vs. 71 years).
The comparison between Ile68Leu ATTRm and Val122Ile
ATTRm is summarized in Table 4.
Estimation of penetrance
During the study period, 55 unaffected Ile68Leu mutation carri-
ers were identified through family screening. Median age at first
evaluation was 49 (43–56) years and 44% were males. The cumu-
lative onset of symptomatic disease according to age is reported
in Figure 1 and is consistent with a late and incomplete penetrance
(50% at age 71).
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Table 3 Echocardiographic findings
Ile68leu (n= 67) ATTRwt (n= 82) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diastolic IVS, mm, median (IQR) 17 (15–20) 17 (15–19) 0.850
Diastolic LV PW, mm, median (IQR) 16 (14–18) 15 (14–18) 0.744
Mean diastolic LV wall thickness, mm, median (IQR) 17 (15–19) 17 (15-19) 0.858
Mean diastolic LV wall thickness/BSA, median (IQR) 9 (8-10) 9 (8-10) 0.779
Left atrial diameter, mm, median (IQR) 47 (44–51) 47 (44–52) 0.940
LVEF, %, median (IQR) 51 (43–60) 50 (43–62) 0.777
LVEF <40%, n (%) 14 (21) 17 (21) 0.999
LVEF 40–49%, n (%) 14 (21) 17 (21)
LVEF ≥50%, n (%) 39 (58) 48 (58)
LVEDD, mm, median (IQR) 48 (45–51) 46 (42–50) 0.038
LVESD, mm, median (IQR) 35 (30–38) 32 (28–37) 0.109
LVEDD/BSA, median (IQR) 26 (24–27) 25 (23–27) 0.062
LVESD/BSA, median (IQR) 19 (16–21) 17 (16–21) 0.307
E-wave DT, ms, median (IQR) 165 (140–204) 168 (145–195) 0.900
Restrictive filling pattern, n (%) 23 (37) 26 (34) 0.683
Pericardial effusion, n (%) 32 (50) 39 (49) 0.940
LV mass, g/m2 BSA, median (IQR) 208 (173–247) 208 (167–252) 0.923
AV valve thickening, n (%) 44 (69) 47 (59) 0.253
MCF, median (IQR) 13 (10–16) 13 (10–18) 0.847
ATTRwt, wild-type transthyretin amyloidosis; AV, atrioventricular; BSA, body surface area; DT, deceleration time; IQR, interquartile range; IVS, interventricular septum; LV, left
ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MCF, myocardial contraction
fraction; PW, posterior wall.
No comparison is associated with statistical significance after Bonferroni correction.
Table 4 Comparison between Ile68Leu TTR patients from our study vs. Val122Ile TTR patients from the THAOS
registry12
Ile68Leu (n= 67) Val122Ile (n= 91)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men, n (%) 52 (78) 69 (76)
Ethnic descent Caucasian 100% African 87%
Age at diagnosis, years, median (IQR) or mean± SD 71 (65–78) 69±10
BMI, kg/m2, median (IQR) or mean± SD 25 (23–27) 28± 6
Heart rate, b.p.m., median (IQR) or mean± SD 75 (65–80) 80±14
SBP, mmHg, median (IQR) or mean± SD 120 (110–132) 112±17
DBP, mmHg, median (IQR) or mean± SD 80 (70–80) 69±11
NYHA class III–IV, n (%) 18 (27) 42/76 (55)*
NT-proBNP, pg/mL, median (IQR) 3287 (1745–5658) 2734 (2307–4467)
Carpal tunnel syndrome, n (%) 29 (43) 16/55 (29)*
Atrial fibrillation, n (%) 20 (30) 14/27 (52)*
Low QRS voltages, n (%) 18 (29) 22/48 (46)*
Any infarct pattern, n (%) 38 (60) NA
Ischaemic pattern (negative T waves), n (%) 28 (44) NA
Normal ECG, n (%) 5 (8) NA
Diastolic IVS, mm, median (IQR) or mean± SD 17 (15–20) 17± 4
Diastolic LV PW, mm, median (IQR) or mean± SD 16 (14–18) 17± 4
LVEF, %, median (IQR) or mean± SD 51 (43− 60) 51±11
Restrictive filling pattern, n (%) 23 (37) NA
Pericardial effusion, n (%) 32 (50) NA
AV valve thickening, n (%) 44 (69) NA
MCF, median (IQR) or mean± SD 13 (10–16) 16±11
AV, atrioventricular; BMI, body mass index; DBP, diastolic blood pressure; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; IQR, interquartile range; IVS,
interventricular septum; LV, left ventricular; LVEF, left ventricular ejection fraction; MCF, myocardial contraction fraction; NA, not available; NT-proBNP, N-terminal pro brain
natriuretic peptide; NYHA, New York Heart Association; PW, posterior wall; SBP, systolic blood pressure; SD, standard deviation; TTR, transthyretin.
*Percentage related to the subgroup of patients with available data.
© 2018 The Authors
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Figure 1 Cumulative onset of symptomatic disease according
to age in Ile68Leu carriers.
Outcome
Follow-up data were available for all patients. Median and mean
follow-up were 34 (18–60) and 43±8.3months, respectively.
Survival estimated by Cox analysis for Ile68Leu ATTRm patients
was 92% at 1 year, 59% at 3 years, and 37% at 5 years. Although
unadjusted estimated survival was poorer in ATTRwt patients (91%
at 1 year, 54% at 3 years, and 31% at 5 years; Figure 2A), no differ-
ence was present after adjustment for age (Figure 2B). At multivari-
ate analysis, the only variables associated with death were older
age at diagnosis and NYHA class III/IV at presentation (Table 5). To
explore the prognostic role of the Ile68Leu mutation itself, a step-
wise model was constructed using the same covariates in addition
to a forced entry covariate (presence of Ile68Leu). The presence
of Ile68Leu mutation was not significantly associated with survival
(hazard ratio 0.90, 95% confidence interval 0.59–1.38; P= 0.641).
During follow-up, 33 Ile68Leu ATTRm patients were hospitalized
for heart failure, 12 developed atrial fibrillation, and 7 developed
advanced atrioventricular block requiring a permanent pacemaker.
All patients with atrial fibrillation were treated with anticoagula-
tion. No patients received treatment with disease-modifying drugs
or underwent cardiac and/or liver transplant.
No patients with a cardiac phenotype developed neurological
symptoms. Of the three patients with a neurological phenotype,
one died due to causes unrelated to amyloidosis and the other two
were alive at the end of follow-up with no changes in phenotype.
None of the unaffected mutation carriers developed signs and/or
symptoms of the disease.
Discussion
Our study provides the first detailed characterization of the pheno-
type and outcome of patients with Ile68Leu ATTRm and expands
our knowledge on so-called FAC. The mutation is essentially ‘car-
diogenic’, leading to an exclusively or mainly cardiac phenotype
almost in all patients. Although Ile68Leu appears to be endemic in
central-northern Italy, particularly in the Apennines of Tuscany and
Romagna (an area of approximately 15 000 km2; online supplemen-
tary Figure S1), its phenotype is very similar to both ATTRwt and ..
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.. Val122Ile ATTRm, that has been previously described in patients of
African descent.12
The typical Ile68Leu ATTRm patient is Caucasian, older than
70 years, seeks medical attention with heart failure symptoms, and
receives the correct diagnosis of AC almost 1 year after the onset
of these symptoms. In almost 45% of cases, a diagnosis of CTS
precedes the diagnosis of AC by 5–7 years. At presentation, about
20% of patients admitted (mild) neurological symptoms that caused
some walking difficulty. However, in the subset of neurologically
asymptomatic patients who underwent a comprehensive neurolog-
ical examination (n= 9), seven were found to have mild lower limb
sensory-motor abnormalities. The overall clinical picture mimics
that of ATTRwt, with the only exceptions of a slightly younger age
at diagnosis (median age 71 vs. 78 years) and a higher frequency of
(mild) neurological symptoms alongside heart failure.
Although not all the necessary data to calculate mutation pen-
etrance were available, cumulative disease onset according to age
(Figure 1) reaches a plateau (around 50%) only after the seventh
decade of life. This can partially explain why patients only rarely
perceive (and therefore report) a family history of cardiomyopathy
and/or heart failure.
A high frequency of pseudo-infarct pattern and intraventricu-
lar conduction delay, including left anterior hemiblock and bundle
branch block (Table 2), characterized the 12-lead ECG of Ile68Leu
patients. It should be noted that low QRS voltages were present
only in 29% of cases, but the voltage/mass ratio was consistently
low and only 8% of patients had a normal ECG. We confirm
that the imbalanced voltage/mass ratio is a distinctive element of
TTR-related AC and is a potentially useful tool for differential diag-
nosis with hypertrophic cardiomyopathy and hypertensive heart
disease. No significant differences emerged from the comparison
with ATTRwt patients, with the exception of a higher prevalence of
atrial fibrillation at diagnosis, which is probably related to older age.
The echocardiographic profile was homogeneous including a
non-dilated left ventricle, symmetric increase in left ventricular wall
thickness, normal or near normal LVEF (Table 3). Left ventricu-
lar hypertrophy was asymmetric (septum/posterior wall thickness
ratio> 1.5) only in 3/67 patients, and LVEF was often at the lower
end of the normal spectrum. Interestingly, the prevalence of a mild
pericardial effusion and atrioventricular valve thickening (poten-
tially useful red-flags for the differential diagnosis with hypertrophic
cardiomyopathy) was high (50% and 69%, respectively). Only one
third of patients had Doppler signs of a restrictive pathophysiology.
As for the clinical and electrocardiographic profile, the echocardio-
graphic phenotype of Ile68Leu ATTRm was indistinguishable from
that of ATTRwt.
Our data confirm the gender imbalance in patients with
TTR-related AC that has already been observed in previous
studies and led to the hypothesis of a protective or delaying effect
of female sex for myocardial involvement in these patients19–21
(online supplementary Tables S1–S3). Notably, male prevalence
was higher amongst affected patients (78%) than in unaffected
mutation carriers (44%). Median age of affected females was
4 years older than males at presentation. The severity of AC
tended to be milder in females with a lower left ventricular wall
thickness and a lower prevalence of restrictive filling pattern. It is
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Figure 2 Kaplan–Meier survival curve (A) and Cox age-adjusted survival (B) in Ile68Leu ATTRm and ATTRwt patients. ATTRm,
transthyretin-related hereditary amyloidosis; ATTRwt, wild-type transthyretin amyloidosis.
Table 5 Univariate and multivariate analysis for survival in Ile68Leu ATTRm patients
Univariate Multivariate
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at diagnosis (for each
1-year increase)
1.07 (1.02–1.12) 0.002 1.07 (1.03–1.11) 0.002
Male gender 0.89 (0.39–2.07) 0.793
Autonomic involvement 0.59 (0.14–2.46) 0.467
Atrial fibrillation 1.77 (0.89–3.52) 0.104
LVEF 0.97 (0.94–1.0) 0.030
MCF 0.97 (0.92–1.03) 0.316
NYHA class III/IV 3.71 (1.9–7.24) <0.001 4.01 (1.98–8.16) 0.0001
Heart rate 1.00 (0.98–1.02) 0.824
IVS thickness 1.07 (0.97–1.18) 0.156
eGFR 0.97 (0.95–0.99) 0.001*
NT-proBNP 1.00 (1.00–1.00) 0.426
Systolic blood pressure 0.98 (0.96–1.00) 0.067
Restrictive filling pattern 1.35 (0.68–2.70) 0.386
Low QRS voltage 1.02 (0.51–2.06) 0.954
ATTRm, transthyretin-related hereditary amyloidosis; CI, confidence interval; eGFR, estimated glomerular filtration rate; IVS, interventricular septum; LVEF, left ventricular
ejection fraction; MCF, myocardial contraction fraction; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association.
In bold, variables considered in the multivariate model.
*Not considered in the multivariate model for missing data.
also worth noting that initial symptoms were neurological in 2/15
females but only in 1/52 males.
An analogy similar to the one between Ile68Leu ATTRm and
ATTRwt found in this study emerges when comparing Ile68Leu
ATTRm to Val122Ile ATTRm patients reported in the THAOS
registry.12 Specifically, they share the advanced age at presentation,
a high prevalence of CTS, and an echocardiographic phenotype
with symmetric hypertrophy and a normal or near normal LVEF.
More in general, our findings confirm the existence of a close
genotype–phenotype correlation in TTR-related amyloidosis, with
some forms (due to Ile68Leu and Val122Ile in particular) associated .
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..
..
. with a predominantly cardiac involvement. The exact mechanism
that starting from different mutations leads to the infiltration of
specific organs, however, remains unclear and it cannot be excluded
that local tissue factors are also involved, along with a central
commitment represented by the mutation.
The natural history of Ile68Leu ATTRm is characterized by high
mortality (41% at 3 years and 63% at 5 years) with no significant
difference from ATTRwt after age adjustment of the Kaplan–Meier
curves (Figure 2). Notably, Val122Ile ATTRm patients have been
shown to have a worse outcome than ATTRwt patients22: this
reinforces the hypothesis23 that both biological and social factors
© 2018 The Authors
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(including a worse access to care) can explain outcome of Val122Ile
African American patients in the USA.
Age at diagnosis and advanced heart failure symptoms at presen-
tation were the only factors independently associated with mortal-
ity in Ile68Leu ATTRm. However, our search for risk factors was
limited by missing laboratory data and due to this limitation it was
not possible to stratify patients’ survival according to the scores
proposed by Grogan et al.24 and Gillmore et al.25
Limitations
Although this is the largest study describing the Ile68Leu TTR
mutation, the absolute number of patients is limited, as is that
of the family members who were evaluated. Genetic analysis was
limited to the TTR gene, while haplotype analysis (that could have
demonstrated a common founder effect) was not carried out. Only
standard echocardiographic data were analysed in each patient,
whereas tissue Doppler, strain and right ventricular function were
not systematically recorded due to the long recruitment period.
The same limitations apply to N-terminal pro brain natriuretic
peptide, that was collected only in the last 13 years of the study, as
was troponin. The possible phenotypic evolution during the natural
history of the disease has been only partially captured due to the
study design. Finally, while survival data were accurately collected
for all patients, the exact cause of death was not systematically
recorded.
Clinical implications
The Ile68Leu TTR mutation is a cause of FAC that has not been
systematically described to date and leads to a phenotype similar to
ATTRwt. Awareness of these findings is essential for a differential
diagnosis with late-onset hypertrophic cardiomyopathy and can
appropriately guide the choice of medical treatment.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Geographic origin of Ile68Leu patients.
Table S1. Baseline characteristics of Ile68Leu ATTRm patients
according to gender.
Table S2. Electrocardiographic findings among Ile68Leu ATTRm
patients according to gender.
Table S3. Echocardiographic findings among Ile68Leu ATTRm
patients according to gender.
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